Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury
Authors
Cubero, Francisco JavierZoubek, Miguel Eugenio
Hu, Wei
Peng, Jin
Zhao, Gang
Nevzorova, Yulia A.
Al Masaoudi, Malika
Bechmann, Lars P.
Boekschoten, Mark V.
Muller, Michael
Preisinger, Christian
Gassler, Nikolaus
Canbay, Ali E.
Luedde, Tom
Davis, Roger J.
Liedtke, Christian
Trautwein, Christian
Document Type
Journal ArticlePublication Date
2016-04-01Keywords
APAPMouse Model
Gene Regulation
Pharmacologic Treatment
Biochemistry
Cell Biology
Cellular and Molecular Physiology
Gastroenterology
Molecular Biology
Metadata
Show full item recordAbstract
BACKGROUND and AIMS: c-Jun N-terminal kinase (JNK) 1 and JNK2 are expressed in hepatocytes and have overlapping and distinct functions. JNK proteins are activated via phosphorylation in response to acetaminophen- or carbon tetrachloride (CCl4)-induced liver damage; the level of activation correlates with the degree of injury. SP600125, a JNK inhibitor, has been reported to block acetaminophen-induced liver injury. We investigated the role of JNK in drug-induced liver injury (DILI) in liver tissue from patients and in mice with genetic deletion of JNK in hepatocytes. METHODS: We studied liver sections from patients with DILI (due to acetaminophen, phenprocoumon, nonsteroidal anti-inflammatory drugs, or autoimmune hepatitis) or patients without acute liver failure (controls) collected from a DILI Biobank in Germany. Levels of total and activated (phosphorylated) JNK were measured by immunohistochemistry and Western blotting. Mice with hepatocyte-specific deletion of Jnk1 (Jnk1(Deltahepa)) or combination of Jnk1 and Jnk2 (Jnk(Deltahepa)), as well as Jnk1-floxed C57BL/6 (control) mice, were given injections of CCl4 (to induce fibrosis) or acetaminophen (to induce toxic liver injury). We performed gene expression microarray and phosphoproteomic analyses to determine mechanisms of JNK activity in hepatocytes. RESULTS: Liver samples from DILI patients contained more activated JNK, predominantly in nuclei of hepatocytes and in immune cells, than healthy tissue. Administration of acetaminophen to Jnk(Deltahepa) mice produced a greater level of liver injury than that observed in Jnk1(Deltahepa) or control mice, based on levels of serum markers and microscopic and histologic analysis of liver tissues. Administration of CCl4 also induced stronger hepatic injury in Jnk(Deltahepa) mice, based on increased inflammation, cell proliferation, and fibrosis progression, compared with Jnk1(Deltahepa) or control mice. Hepatocytes from Jnk(Deltahepa) mice given acetaminophen had an increased oxidative stress response, leading to decreased activation of adenosine monophosphate-activated protein kinase, total protein adenosine monophosphate-activated protein kinase levels, and pJunD and subsequent necrosis. Administration of SP600125 before or with acetaminophen protected Jnk(Deltahepa) and control mice from liver injury. CONCLUSIONS: In hepatocytes, JNK1 and JNK2 appear to have combined effects in protecting mice from CCl4- and acetaminophen-induced liver injury. It is important to study the tissue-specific functions of both proteins, rather than just JNK1, in the onset of toxic liver injury. JNK inhibition with SP600125 shows off-target effects.Source
Gastroenterology. 2016 Apr;150(4):968-81. doi: 10.1053/j.gastro.2015.12.019. Epub 2015 Dec 19. Link to article on publisher's siteDOI
10.1053/j.gastro.2015.12.019Permanent Link to this Item
http://hdl.handle.net/20.500.14038/28328PubMed ID
26708719Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1053/j.gastro.2015.12.019